- Home
- IVVD vs SRZN Comparison
IVVD vs SRZN Comparison
Compare IVVD & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- SRZN
- Stock Information
- Founded
- IVVD 2020
- SRZN 2015
- Country
- IVVD United States
- SRZN United States
- Employees
- IVVD N/A
- SRZN N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- IVVD Health Care
- SRZN Health Care
- Exchange
- IVVD Nasdaq
- SRZN Nasdaq
- Market Cap
- IVVD 69.0M
- SRZN 72.8M
- IPO Year
- IVVD 2021
- SRZN N/A
- Fundamental
- Price
- IVVD $0.75
- SRZN $10.00
- Analyst Decision
- IVVD Strong Buy
- SRZN Strong Buy
- Analyst Count
- IVVD 3
- SRZN 2
- Target Price
- IVVD $5.85
- SRZN $38.50
- AVG Volume (30 Days)
- IVVD 1.8M
- SRZN 15.0K
- Earning Date
- IVVD 08-13-2025
- SRZN 08-11-2025
- Dividend Yield
- IVVD N/A
- SRZN N/A
- EPS Growth
- IVVD N/A
- SRZN N/A
- EPS
- IVVD N/A
- SRZN N/A
- Revenue
- IVVD $36,688,000.00
- SRZN $11,638,000.00
- Revenue This Year
- IVVD $446.60
- SRZN N/A
- Revenue Next Year
- IVVD $112.63
- SRZN N/A
- P/E Ratio
- IVVD N/A
- SRZN N/A
- Revenue Growth
- IVVD N/A
- SRZN N/A
- 52 Week Low
- IVVD $0.35
- SRZN $5.90
- 52 Week High
- IVVD $2.74
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- IVVD 43.27
- SRZN 61.67
- Support Level
- IVVD $0.70
- SRZN $9.15
- Resistance Level
- IVVD $1.03
- SRZN $10.05
- Average True Range (ATR)
- IVVD 0.07
- SRZN 0.53
- MACD
- IVVD -0.03
- SRZN 0.20
- Stochastic Oscillator
- IVVD 12.75
- SRZN 93.33
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).